Long-Term Safety and Efficacy of Latisse (Bimatoprost 0.03% Solution) for Treatment of Eyelash Hypotrichosis in Subjects with Chemotherapy-Induced and Idiopathic Hypotrichosis

The document reports on a one-year, multicenter, randomized, double-masked, vehicle-controlled study evaluating the long-term safety and efficacy of LATISSE (bimatoprost 0.03% solution) for treating eyelash hypotrichosis in subjects with chemotherapy-induced and idiopathic hypotrichosis. A total of 368 subjects were randomized, with 238 having idiopathic hypotrichosis and 130 having post-chemotherapy hypotrichosis. The study's primary endpoint was the proportion of responders based on a composite measure of Global Eyelash Assessment (GEA) and Eyelash Satisfaction Questionnaire (ESQ) Domain-2 at month 4. Results showed that over 70% of subjects in both populations demonstrated increased eyelash prominence (>1 grade GEA improvement) following daily bimatoprost treatment, with no drug-related serious adverse events reported. The study concluded that daily application of LATISSE to the eyelid margin over a 1-year period was safe, well tolerated, and effective in both idiopathic and post-chemotherapy populations.